Boceprevir
Chemical compound / From Wikipedia, the free encyclopedia
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1.[2][3] It binds to the HCV nonstructural protein 3 active site.[4]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Victrelis |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a611039 |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 75%[1] |
Elimination half-life | 3.4 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.226.246 |
Chemical and physical data | |
Formula | C27H45N5O5 |
Molar mass | 519.687 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
It was initially developed by Schering-Plough,[5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011.[6] In January 2015, Merck announced that they would be voluntarily withdrawing Victrelis from the market due to the overwhelming superiority of newer direct-acting antiviral agents, such as ledipasvir/sofosbuvir.[7]